While our Low Dose Program offers the flexibility to try microdosing if that is something youre interested in, we can also adjust the medication so you can experience the results youre looking for while still staying well below standard high doses
doesnt apply to non-melanoma skin cancer that was considered cured via simple excision alone). Thats clinically meaningful oncology guidelines often use 5-year remission as a recurrence threshold, and non-melanoma skin cancer is broadly considered low-risk once excised
The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable
Compounded GLP-1s : Made by specialized pharmacies when brand-name drugs are in shortage
Resources on SeekPeptides cover the evolving research on dual versus single incretin receptor targeting for anyone who wants to follow the science as it develops
I think waking up in the morning and continuing to care about your weight means you're biased to participate in a longitudinal program and to continue to engage in a way that we haven't seen before